Swiss Healthcare Group Galenica Breaks CHF4 Billion Sales Mark

The company met its own target of increasing sales by 4-6% to post record revenues.

Group results met analysts' expectations that had forecast a sales increase to CHF4.14 billion.

Galenica said growth was broadly based across all business sectors. Its new diagnostics business sector also contributed to sales growth, it added.

Sales growth was driven in particular by strong demand for prescription medicines, including GLP-1-based weight loss products and dietary supplements.

The Logistics and IT division contributed revenues of CHF3.33 billion, an increase of 4.8%.

The second business sector, Products & Care, generated sales of CHF1.82 billion (+6.8 per cent).

The acquired diagnostics service provider Labor Team is now also part of the Products & Diagnostics unit, where it is operates under the name Galenica Diagnostics.

Galenica continues to expect an increase in operating profit (EBIT) of 10 to 12%. It anticipates a dividend at least on a par with the previous year of CHF 2.30 per share.

Translated from German by AI/mga

We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.

Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.

If you have any questions about how we work, write to us at ...

In compliance with the JTI standards

More: SWI swissinfo certified by the Journalism Trust Initiati

You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at ....